What is the recommended protocol for Fiasp (insulin aspart) infusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Protocol for Fiasp (Insulin Aspart) Infusion

For intravenous Fiasp infusion, prepare a standard concentration of 1 unit/mL in normal saline solution and prime the infusion line with 20 mL of the insulin solution before connecting to the patient to ensure accurate dosing. 1

Preparation and Administration

Solution Preparation

  • Dilute Fiasp to a concentration of 1 unit/mL in normal saline solution 1
  • Gently invert the bag several times to ensure proper mixing 1
  • Unopened insulin should be refrigerated at 36-46°F (2-8°C) 1
  • In-use insulin may be kept at room temperature (59-86°F) for up to 30 days 1

Infusion Line Setup

  • Prime the infusion line with 20 mL of insulin solution before connecting to the patient 2, 1
  • This waste volume ensures accurate dosing by removing air bubbles and saturating binding sites in the tubing 2
  • Use dedicated infusion lines for insulin to prevent medication errors 2

Dosing and Monitoring Protocol

Initial Dosing

  • For critically ill patients: Start with continuous intravenous insulin infusion 2
  • For diabetic ketoacidosis: Initial bolus of 0.15 U/kg followed by continuous infusion at 0.1 U/kg/hour 1
  • For standard hyperglycemia management: Follow institutional protocol with dose adjustments based on blood glucose readings 2

Monitoring Requirements

  • Check blood glucose every 1-2 hours until stable, then every 4 hours 2
  • Target glucose range: 140-180 mg/dL for most critically ill patients 1
  • For cardiac surgery patients: Target 110-140 mg/dL 1
  • Monitor potassium levels closely as hypokalemia is a contraindication to insulin therapy 1

Dose Adjustments

  • Adjust infusion rate according to validated protocols 1
  • Aim to reduce glucose by 50-75 mg/dL per hour 1
  • Reduce infusion rate to 0.05-0.1 units/kg/hour when glucose levels approach target 1

Transitioning from IV to Subcutaneous Insulin

Timing of Transition

  • Transition when blood glucose levels are stable for at least 24 hours 2
  • Transition should coincide with resumption of oral feeding 2
  • Stop IV insulin when hourly output is ≤0.5 IU/h 2
  • Consider continuing IV insulin if output is ≥5 IU/h, which indicates major insulin resistance 2

Dosing for Transition

  • Calculate subcutaneous insulin dose based on IV requirements:
    • Option 1: 50% of total IV insulin dose as basal insulin, 50% as rapid-acting insulin 2
    • Option 2: 80% of IV insulin dose as basal insulin plus rapid-acting insulin at first meal 2
  • Administer basal insulin immediately after stopping IV infusion 2
  • Administer rapid-acting insulin at the first meal, adjusted to carbohydrate intake 2
  • For patients not previously on insulin with IV infusion <24 hours: Start with 0.5-1 IU/kg (half basal, half rapid-acting) 2

Special Considerations

Hypoglycemia Management

  • For blood glucose <3.3 mmol/L (60 mg/dL): Administer glucose immediately even without symptoms 2
  • For blood glucose 3.8-5.5 mmol/L (70-100 mg/dL) with symptoms: Administer glucose 2
  • Prefer oral glucose for conscious patients; use IV glucose for unconscious patients 2

Advantages of Fiasp in Infusion Pumps

  • Fiasp has shown better post-prandial glycemic control compared to standard insulin aspart in pump settings 3
  • Studies show reduced time in hypoglycemia with Fiasp compared to standard insulin aspart 4
  • Fiasp has demonstrated no increased risk of infusion set clogging compared to standard insulin aspart 5

Potential Complications and Mitigation

Common Issues

  • Unexplained hyperglycemia may be more common with Fiasp than with standard insulin aspart 5
  • Premature infusion set changes might be needed more frequently with Fiasp 5
  • Monitor for hypokalemia, which is a contraindication to insulin therapy 1

Safety Measures

  • Insulin is a high-risk medication; implement a systems-based approach to reduce errors 2
  • Use standardized protocols for insulin dosing and monitoring 2
  • Consider computerized decision-support systems for better glucose control than paper-based systems 2
  • Perform routine and frequent assessment of glucose metrics 2

By following this protocol for Fiasp insulin infusion, healthcare providers can optimize glycemic control while minimizing the risk of complications in hospitalized patients.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.